Principal Research Scientist, Centre of Excellence for Antimatter-Matter Studies (CAMS) and Node Director, Australian Nuclear Science and Technology Organisation (ANSTO), Menai, NSW 2234, Australia +61 2 9717 3125 ; +61 2 9543 7179 ;
Expert Opin Drug Discov. 2007 May;2(5):659-72. doi: 10.1517/17460441.2.5.659.
The contribution of positron emission tomography (PET) to the drug discovery and development (D3) pipeline has been inhibited by the short half-lifes of PET radioisotopes, (11)C and (18)F, poor availability and the high cost of infrastructure. Copper-64 ((64)Cu) has a 12.7 h half-life, simple yet flexible radiochemistry and imaging characteristics that make it ideal for a wider application across the D3 arena. Recent scientific breakthroughs in the production of (64)Cu show that it's, commercial production can be made more widely available. More importantly, for pharmaceutical research and development programmes wishing to incorporate the high sensitivity and spatial resolution of PET, but no desire to implement and maintain expensive radiochemistry infrastructure, (64)Cu is an exciting option.
正电子发射断层扫描（PET）对药物发现和开发（D3）管道的贡献受到 PET 放射性同位素（11）C 和（18）F 半衰期短、可用性差以及基础设施成本高的限制。铜-64（（64）Cu）的半衰期为 12.7 小时，具有简单而灵活的放射化学特性和成像特性，使其非常适合更广泛地应用于 D3 领域。（64）Cu 生产方面的最新科学突破表明，它的商业生产可以更加广泛地供应。更重要的是，对于希望结合 PET 的高灵敏度和空间分辨率，但不希望实施和维护昂贵的放射化学基础设施的制药研究和开发计划，（64）Cu 是一个令人兴奋的选择。
